T2 Biosystems Inc (TTOO)
3.005
0.00 (0.00%)
USD |
NASDAQ |
Mar 28, 15:30
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 14.82M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -93.93% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.3756 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -2.127 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.98% |
Profile
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease. |
URL | https://www.t2biosystems.com |
Investor Relations URL | http://investors.t2biosystems.com/ |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 23, 2024 (est.) |
Last Earnings Release | Feb. 15, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease. |
URL | https://www.t2biosystems.com |
Investor Relations URL | http://investors.t2biosystems.com/ |
HQ State/Province | Massachusetts |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 23, 2024 (est.) |
Last Earnings Release | Feb. 15, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |